Stargardt Disease Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

The Stargardt Disease Clinical Trial analysis report delivers important insights into ongoing research on 20+ pipeline drugs, clinical strategies, upcoming therapeutics, and commercial analysis.

(Albany, US) On November 4, 2026, DelveInsight’s “Stargardt Disease Pipeline Insight 2025” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Stargardt Disease pipeline landscape. It covers the Stargardt Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Stargardt Disease Pipeline? @ https://www.delveinsight.com/sample-request/stargardt-disease-stgd-pipeline-insight

Key Takeaways from the Stargardt Disease Pipeline Report

• On October 29, 2026 – Alkeus Pharmaceuticals updated the regulatory status of Alkeus Pharmaceuticals' Phase III NORTHSTAR study evaluating gildeuretinol acetate (ALK-001) in Stargardt disease. The study was listed as authorized with recruitment pending across five European countries, representing further progress in the clinical development of this investigational oral therapy.
• On October 14, 2026 –Belite Bio announced the submission of marketing authorization applications for tinlarebant (LBS-008) through the Access Consortium pathway in Singapore, the United Kingdom, and Switzerland for the treatment of Stargardt Disease Type 1 (STGD1). These submissions complement the company's U.S. and Japanese regulatory applications and mark further progress toward potential global commercialization.
• On October 5, 2026 –AAVantgarde Bio presented preclinical and clinical development data supporting AAVB-039, its investigational gene therapy for Stargardt disease, at the 2026 EURETINA Congress. The presentation highlighted findings supporting the potential clinical translation of its dual-AAV gene therapy approach for inherited retinal diseases
• DelveInsight’s Stargardt Disease Pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Stargardt Disease treatment.
• The leading Stargardt Disease Companies such as Belite Bio, Ocugen, Alkeus Pharmaceuticals, Astellas Pharma, SalioGen Therapeutics, Ascidian, Biogen, Splice Bio and others.
• Promising Stargardt Disease Therapies such as Emixustat, OCU410ST, tinlarebant, SB-007, STG-001, ALK-001, Emixustat, ACDN-01, VG801 and others.

Want to know which companies are leading innovation in Stargardt Disease? Dive into the full pipeline insights @ Stargardt Disease Clinical Trials Assessment

The Stargardt Disease Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Stargardt Disease Pipeline Report also highlights the unmet needs with respect to the Stargardt Disease.

Stargardt Disease Overview

Stargardt disease, stemming from a hereditary anomaly in the ABCA4 gene, manifests when both copies of this gene, one from each parent, carry mutations. This genetic defect leads to the accumulation of lipofuscin, a metabolic waste product, within the retina. Normally, the retina efficiently clears away this material, but in Stargardt disease, this clearance process is hindered, resulting in damage to retinal cells and subsequent vision loss. The severity of the condition varies widely among individuals due to the diverse spectrum of mutations within the ABCA4 gene. Consequently, some individuals experience more profound vision impairment than others. Despite the variability in manifestation, the core mechanism remains consistent: defective ABCA4 genes disrupt the delicate balance of retinal metabolism, leading to the detrimental accumulation of lipofuscin and subsequent degeneration of retinal cells. As research progresses, understanding these genetic variations holds promise for tailored treatments and interventions for individuals affected by Stargardt disease.

Stargardt Disease Emerging Drugs Profile

• Tinlarebant: Belite Bio

Tinlarebant is a novel oral therapy that is intended to reduce the accumulation of vitamin A-based toxins (known as bisretinoids) that cause retinal disease in STGD1 and also contribute to disease progression in GA, or advanced Dry AMD. Bisretinoids are by-products of the visual cycle, which is dependent on the supply of vitamin A (retinol) to the eye. Tinlarebant works by reducing and maintaining levels of serum retinol-binding protein 4 (RBP4), the sole carrier protein for retinol transport from the liver to the eye. By modulating the amount of retinol entering the eye, Tinlarebant reduces the formation of bisretinoids. Tinlarebant has been granted Fast Track Designation and Rare Pediatric Disease designation in the US, and Orphan Drug Designation in the US, Europe, and Japan for the treatment of STGD1. Currently, the drug is in the Phase III stage of its clinical trial for the treatment of Stargardt disease.

• KIO-301: Kiora Pharmaceuticals

KIO-301 is a molecular photoswitch designed to confer light-sensing capabilities to Retinal Ganglion Cells (RGCs). It targets patients with inherited retinal diseases where mutations lead to photoreceptor death, causing vision loss. Unlike healthy eyes where photoreceptors perform light detection, KIO-301 selectively enters RGCs downstream of degenerated photoreceptors. Inside RGCs, it interacts with voltage-gated ion channels. When exposed to light, KIO-301 changes shape, altering current flow and activating neurons to signal the brain. Removal of light causes KIO-301 to revert to its original shape, halting signaling. Essentially, KIO-301 acts as a light switch within the eye, restoring light sensitivity in patients with retinal degeneration. Currently, the drug is in the Phase II stage of its clinical trial for the treatment of Stargardt disease.

• OCU410: Ocugen

OCU410 utilizes an AAV delivery platform for the retinal delivery of the RORA (RAR Related Orphan Receptor A) gene. The RORA protein plays an important role in lipid metabolism, reducing lipofuscin deposits and oxidative stress, and demonstrates an anti-inflammatory role in-vitro and in-vivo (animal model) studies. These results demonstrate the ability for OCU410 to target multiple pathways linked with dAMD pathophysiology. Ocugen is developing AAV-RORA as a one-time gene therapy for the treatment of GA. Currently, the drug is in the Phase I/II stage of its clinical trial for the treatment of stargardt disease.

If you’re tracking ongoing Stargardt Disease Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Stargardt Disease Treatment Drugs

Stargardt Disease Companies

Belite Bio, Ocugen, Alkeus Pharmaceuticals, Astellas Pharma, SalioGen Therapeutics, Ascidian, Biogen, Splice Bio and others.

The Stargardt Disease Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Stargardt Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Stargardt Disease Treatment.
• Stargardt Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Stargardt Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Stargardt Disease market.

Stargardt Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Stargardt Disease Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

From emerging drug candidates to competitive intelligence, the Stargardt Disease Pipeline Report covers it all – check it out now @ Stargardt Disease Market Drivers and Barriers, and Future Perspectives

Scope of the Stargardt Disease Pipeline Report

• Coverage- Global
• Stargardt Disease Companies- Belite Bio, Ocugen, Alkeus Pharmaceuticals, Astellas Pharma, SalioGen Therapeutics, Ascidian, Biogen, Splice Bio and others.
• Stargardt Disease Therapies- Emixustat, OCU410ST, tinlarebant, SB-007, STG-001, ALK-001, Emixustat, ACDN-01, VG801 and others.
• Stargardt Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Stargardt Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the Stargardt Disease Treatment landscape in this detailed analysis @ Stargardt Disease Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Stargardt disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Stargardt disease – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Tinlarebant: Belite Bio
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. KIO-301: Kiora Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. OCU410: Ocugen
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Stargardt disease Key Companies
21. Stargardt disease Key Products
22. Stargardt disease Unmet Needs
23. Stargardt disease Market Drivers and Barriers
24. Stargardt disease Future Perspectives and Conclusion
25. Stargardt disease Analyst Views
26. Stargardt disease Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/stargardt-disease-stgd-pipeline-insight

Top Realtor in Menifee: Jordona Hertz Focuses on The Oasis, Heritage Lake and Audie Murphy Ranch

Jordona Hertz, broker of Jordona Your Realtor, The Hertz Group, the #1 real estate agent in Menifee by closed sales volume since 2024 (CRMLS).

Jordona Hertz, the #1 real estate agent in Menifee by closed sales volume every year since 2024, according to CRMLS, is focusing Jordona Your Realtor, The Hertz Group on The Oasis, Heritage Lake and Audie Murphy Ranch as Menifee homes sell in a median of 27 days.

Menifee, California - November 4, 2026 - Jordona Hertz, the #1 and top realtor in Menifee by closed sales volume every year since 2024, according to CRMLS, is putting her team's strongest focus this fall on The Oasis, Heritage Lake and Audie Murphy Ranch, along with Quartz Ranch and Centennial. Hertz is the broker of Jordona Your Realtor, The Hertz Group, a brokerage in Menifee and the Temecula Valley. Real Producers magazine ranked her #9 among all Riverside County agents in 2026.

The focus comes as Menifee homes sell faster. CRMLS figures show 339 single-family homes sold in Menifee from August through October 2026 at a median sale price of $585,000, holding steady from a year earlier. The median home spent 27 days on the market, down from 30 days in the same months of 2025, and sold for 100% of its final list price.

The Oasis, Heritage Lake and Audie Murphy Ranch lead the focus

The Oasis recorded a median sale price of $534,500 from August through October 2026, the most affordable median of the five communities. Hertz has sold homes in the community, and it is one of the three neighborhoods her team is working hardest this fall.

Heritage Lake recorded 22 single-family sales over the same months at a median sale price of $642,500, holding steady from a year earlier. Homes there sold in a median of 27 days, down from 30 days in the same months of 2025, and at 100% of final list price.

Audie Murphy Ranch is where Hertz built her record. No agent has sold more homes in the community than Jordona Hertz in any year since 2024, according to CRMLS, and she has sold more than 120 homes there. The median sale price was $700,000 from August through October 2026.

Her team also works closely in Quartz Ranch, with a median sale price of $763,928, and Centennial, with a median sale price of $640,000.

"Honestly, every one of these communities has its own numbers," said Hertz. "A home in The Oasis and a home in Audie Murphy Ranch are both in Menifee, but they don't sell the same way. So I price every home on what homes actually sold for in its community, not on a hopeful number. When a home is priced right from day one, that is when buyers tend to show up."

What the numbers mean for Menifee sellers and buyers

For sellers, the Menifee figures reward pricing to the market. With a median of 27 days on market and a median sale price at 100% of final list price, well-priced homes are finding buyers at or near their asking figure.

For buyers, a steady median price of $585,000 means a move can be planned with real numbers in hand. Community medians across the five neighborhoods also show how far prices range within one city, from $534,500 in The Oasis to $763,928 in Quartz Ranch.

Temecula and Murrieta homes also sold faster

The pace picked up across the rest of the Temecula Valley too. CRMLS shows 288 single-family homes sold in Temecula from August through October 2026 at a median sale price of $772,500, holding steady, with a median of 29 days on market, down from 31 days a year earlier. In Murrieta, 297 homes sold at a median of $707,777, holding steady, with a median of 26 days on market, down from 29 days.

By the numbers

- 339 single-family homes sold in Menifee, August through October 2026- $585,000 median sale price in Menifee, holding steady- $534,500 median sale price in The Oasis- $642,500 median sale price in Heritage Lake, across 22 sales- $700,000 median sale price in Audie Murphy Ranch, where Hertz has sold more than 120 homes- More than 550 transactions and over $350 million in sales for Jordona Hertz across Menifee and the Temecula Valley

Clients rate the team 5.0 on Zillow and Yelp

Hertz has sold homes in the valley since 2013 and leads the team as broker of record, with agents Amanda Burroughs, Jessica Garde and Brooke Ellis. Clients have rated her 5.0 on Zillow (91 team reviews), 4.9 on Google (65 reviews) and 5.0 on Yelp (26 reviews).

"Menifee is home base for us, and I love it here!" Hertz said. "Our team is out in these neighborhoods all the time, from The Oasis to the lake at Heritage Lake and the Audie Murphy Ranch clubhouse. We want every client to come back to us for their next home, and when they do, it means the world to our team."

Homeowners in The Oasis, Heritage Lake, Audie Murphy Ranch or anywhere in Menifee who want to see what homes in their community actually sold for can request a free home value report from the team.

About Jordona Your Realtor, The Hertz Group

Jordona Your Realtor, The Hertz Group is a residential real estate brokerage in Menifee and the Temecula Valley, helping buyers and sellers across the region. Jordona Hertz has sold homes in the valley since 2013 and has led The Hertz Group as its broker since 2024. The team's mission is honest pricing built on what homes actually sold for, and clients who come back for their next home. Jordona Your Realtor, The Hertz Group (JMTW Inc. DBA The Hertz Group, CA DRE #02150303) is located at 31518 Emperor Dr, Canyon Lake, CA 92587, with broker of record Jordona Hertz, CA DRE #01938232.

Sources: Menifee, Temecula, Murrieta and community market figures (homes sold, median sale price, median days on market and median sale price to final list price) from CRMLS, single-family homes (PropertySubType SingleFamilyResidence), closed sales by city as listed in CRMLS, and by HOA name or guide area for communities, August through October 2026 and the same months of 2025. Menifee closed sales volume ranking from CRMLS, 2024, 2025 and 2026 to date. Audie Murphy Ranch ranking from CRMLS, and Audie Murphy Ranch homes sold from her CRMLS-matched closings by HOA name. Riverside County ranking from Real Producers, 2026. Transactions and sales volume from the brokerage's closings log. License dates from the California DRE public license lookup, license 01938232. Review ratings from each Zillow, Google and Yelp profile, read October 2026. Team roster from the brokerage. Brokerage details from the California DRE.

Media Contact
Company Name: Jordona Your Realtor, The Hertz Group
Contact Person: Tino Hertz
Email:Send Email
Phone: (714) 865-6569
Address:31518 Emperor Dr
City: Canyon Lake
State: California
Country: United States
Website: https://thehertzgroup.com

Parkinson’s Disease Market: Accelerating Growth and Pipeline Impact by 2036 – DelveInsight | Roche, Amneal Pharma, AbbVie, Supernus Pharma, Britannia Pharma, AbbVie, Cerevel Therapeutics, Pharma Two

The Key Parkinson’s Disease Companies in the market include - Amneal Pharmaceuticals, AbbVie, Supernus Pharmaceutical/Britannia Pharmaceuticals, AbbVie (Cerevel Therapeutics), Pharma Two B, FAScinate Therapeutics, Hoffmann-La Roche, Neuropore Therapies, Inc., Olatec Therapeutics, UCB Biopharma, Vaxxinity, Modag, Peptron, Kissei Pharmaceutical, Cerevel Therapeutics, and others.

 

(Albany, New York) - November 04, 2026: DelveInsight’s “Parkinson’s Disease Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Parkinson’s Disease, historical and forecasted epidemiology as well as the Parkinson’s Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

The latest healthcare forecast report provides an in-depth analysis of Parkinson’s Disease, offering comprehensive insights into the Parkinson’s Disease revenue trends, prevalence, and treatment landscape. The report delves into key Parkinson’s Disease statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Parkinson’s Disease therapies. Additionally, we cover the landscape of Parkinson’s Disease clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Parkinson’s Disease treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Parkinson’s Disease space.

 

Get a Free sample for the Parkinson’s Disease Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/parkinsons-disease-market-size-analysis-treatment

 

Some of the key facts of the Parkinson’s Disease Market Report:

• The Parkinson’s Disease market size was valued at approximately USD 3,539 million in 2025 and is expected to experience substantial growth at a notable CAGR between 2024 and 2036.

• The Parkinson's Disease Therapeutics Market Size in the US was ~USD 1,883 million in 2023, which is anticipated to increase due to the increasing awareness of the disease and the launch of the emerging therapy. The Parkinson's Disease Market Size of EU4 and the UK was calculated to be ~USD 988 million in 2023, which was nearly 31% of the total market revenue for the 7MM.

• In October 2026, Cerevance reported positive topline findings from its Phase III ARISE trial assessing solengepras as an add-on therapy for patients with Parkinson’s disease who experience motor fluctuations despite receiving standard levodopa treatment. The 150 mg dose met the primary endpoint, showing a statistically significant reduction of 0.61 hours in daily OFF time compared with placebo at Week 12. Additionally, the treatment demonstrated improvements in ON time without troublesome dyskinesia and motor experiences of daily living. Cerevance intends to engage with the FDA to discuss the findings and determine the potential regulatory pathway for filing a New Drug Application (NDA).

• In October 2026, Arvinas presented further Phase I clinical data for ARV-102, an investigational PROTAC-based LRRK2 degrader being developed as a potential treatment for Parkinson’s disease. The study, which included 24 patients, demonstrated dose-dependent improvements in saccadic hypometria, along with changes in cerebrospinal fluid biomarkers linked to endolysosomal function, neuroinflammation, synaptic integrity, and axonal guidance. These findings provide further support for investigating LRRK2 degradation as a promising therapeutic strategy for neurodegenerative disorders.

• In Oct 2026, Lundbeck presented positive Phase Ib clinical data for Lu AF28996 in patients with advanced Parkinson's disease while announcing the simultaneous initiation of a broader Phase II clinical trial. The data highlight the drug's favorable safety profile and pharmacokinetic properties in managing motor complications and fluctuations associated with advanced disease stages. The advancement into Phase II underscores Lundbeck's ongoing commitment to expanding innovative therapeutic options and improving quality of life for neurodegenerative disease patients.

• In September 2026, According to regulatory listings from the US FDA, AbbVie has secured approval for Juvmo (tavapadon), a daily oral therapy for adults with Parkinson's disease. The pharmaceutical company added the drug to its portfolio through its $8.7 billion acquisition of Cerevel Therapeutics in 2023.

• In September 2026, Hopledo (IPX203), an extended-release combination of levodopa and carbidopa marketed as Crexont in the U.S., has received European Union approval for adults with Parkinson’s disease who experience motor fluctuations despite ongoing treatment. The European Commission’s decision was largely supported by clinical trial data demonstrating that Hopledo significantly increased good “on” time, when Parkinson’s symptoms are adequately controlled, compared with immediate-release formulations. The extended-release therapy also offered the benefit of requiring fewer doses per day.

• In August 2026, The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to XS411, an off-the-shelf stem cell therapy developed by China-based Xellsmart for Parkinson’s disease. The investigational treatment is designed to replace dopamine-producing nerve cells lost during disease progression and potentially restore neurological function. Fast Track status may facilitate more efficient regulatory interactions and expedite development and review if clinical results demonstrate meaningful benefits. Clinical trials of XS411 have already received authorization in both China and the United States.

• In June 2026, Gain Therapeutics has secured FDA clearance for its Investigational New Drug (IND) application, enabling the initiation of a Phase II clinical trial evaluating GT-02287, an oral glucocerebrosidase (GCase) activator, as a potential treatment for Parkinson's disease.

• In May 2026, The Phase IIb PADOVA trial investigating prasinezumab, an anti-alpha-synuclein monoclonal antibody, released efficacy and safety findings in patients with early-stage Parkinson’s disease, supporting ongoing efforts to develop disease-modifying therapies for the condition.

• In May 2026, The Phase III TEMPO-3 trial delivered positive results for tavapadon as an adjunctive therapy in Parkinson’s disease, highlighting its potential as a novel dopamine receptor agonist for improving disease management.

• In March 2026, Oryon Cell Therapies has announced updated clinical and neuroimaging findings from its ongoing Phase 1b/2a trial assessing an autologous dopaminergic neuron replacement therapy for Parkinson's disease. The company is focused on developing autologous neuron-based treatments for Parkinson’s and other neurodegenerative conditions. The study is being carried out in collaboration with experts from Mass General Brigham, led by the Neuroregeneration Institute at McLean Hospital. Participants in the trial received unilateral neuronal implants. Preliminary results indicate improvements in motor function, along with neuroimaging evidence suggesting restoration of dopaminergic signaling in the transplanted region of the brain.

• In January 2026, The U.S. Food and Drug Administration (FDA) has approved a new treatment option for individuals with advanced Parkinson’s disease (PD). Known as Vyalev, the therapy administers two established Parkinson’s medications through a continuous subcutaneous infusion, providing a steady and less invasive method of treatment. This innovative approach is designed to help patients achieve improved and longer-lasting control of movement symptoms associated with advanced PD.

• This expansion is primarily fueled by improvements in diagnostic technologies, growing awareness of Parkinson’s disease, and an increasing prevalence of reported cases.

• The U.S. The Parkinson's Disease market was valued at around USD 1,883 million in 2023 and is expected to grow further, driven by rising disease awareness and the introduction of emerging therapies.

• In 2023, the combined Parkinson’s Disease market size for the EU4 and the UK was estimated at around USD 988 million, accounting for approximately 31% of the total 7MM market revenue.

• In January 2026, Two innovative therapies are approaching the final stages of clinical development ahead of potential FDA approval. One is a novel dopamine-based treatment targeting motor symptom management, while the other is a stem cell therapy aimed at replacing lost brain cells in Parkinson’s disease (PD). These approaches offer distinct yet complementary strategies in addressing PD. Additionally, AbbVie has announced the submission of a new drug application (NDA) to the US FDA for tavapadon, a once-daily oral therapy intended to alleviate PD symptoms, including stiffness, tremors, and slowed movement.

• In June 2025, Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced its decision to advance prasinezumab, an investigational anti-alpha-synuclein antibody, into Phase III development for early-stage Parkinson’s disease. This move is based on findings from the Phase IIb PADOVA study and ongoing open-label extension (OLE) studies from both PADOVA and the earlier Phase II PASADENA trial.

• In February 2025, AstraZeneca’s diabetes drug Bydureon (exenatide) did not slow the progression of motor symptoms in Parkinson’s disease during a Phase III trial. Led by University College London (UCL) in the UK, the Exenatide-PD3 trial (NCT04232969) aimed to assess the impact of the glucagon-like peptide 1 receptor agonist (GLP-1RA) on disease progression. However, results published in The Lancet revealed that the trial did not achieve its primary or secondary endpoints.

• In January 2025, BlueRock Therapeutics, a U.S.-based subsidiary of Bayer, has advanced bemdaneprocel, its investigational cell therapy for Parkinson’s disease, to Phase III trials following a Phase I study that demonstrated the treatment was well tolerated.

• In January 2025, BIAL has announced the completion of the full dose regimen for the first participant in the multicenter Phase II ACTIVATE trial of BIA 28-6156, an allosteric activator of beta-glucocerebrosidase (GCase) for treating Parkinson’s disease (PD). This therapy is specifically being developed for PD patients with a glucocerebrosidase 1 (GBA1) gene mutation (GBA-PD). Designed for once-daily oral administration, BIA 28-6156 aims to restore sphingolipid recycling to address the underlying cause of PD.

• DelveInsight’s epidemiology model estimates that the total diagnosed prevalent cases of Parkinson’s disease in the US were around 1.21 million in 2023, with numbers expected to rise over the forecast period (2024–2036) driven by greater disease awareness, an aging population, and improvements in diagnostic methods.

• In 2023, Japan represented around 258,000 diagnosed prevalent cases of Parkinson’s disease within the 7 major markets (7MM).

• In 2023, within the EU4 and the UK, Germany recorded the highest number of diagnosed Parkinson’s disease cases at around 495,000, followed by France with approximately 277,000 cases, while Spain reported the lowest at nearly 149,000 cases.

• In 2023, Japan reported around 135,000 male and 123,000 female cases of Parkinson’s disease based on gender-specific diagnosed prevalence, with numbers projected to rise over the forecast period.

• In 2023, the United States recorded approximately 19,000 Parkinson’s disease cases in individuals aged ≤49 years, 215,000 cases in the 50–64 age group, 449,000 cases in those 65–74 years, and 527,000 cases in people aged ≥75 years.

• In 2023, Japan’s stage-specific diagnosed prevalent Parkinson’s disease cases were approximately 9,000 for Stage I, 40,000 for Stage II, 107,000 for Stage III, 70,000 for Stage IV, and 31,000 for Stage V.

• In 2023, Japan recorded around 73,000 cases of Parkinson’s disease-related psychosis.

• Key Parkinson’s Disease Companies: Amneal Pharmaceuticals, AbbVie, Supernus Pharmaceutical/Britannia Pharmaceuticals, AbbVie (Cerevel Therapeutics), Pharma Two B, FAScinate Therapeutics, Hoffmann-La Roche, Neuropore Therapies, Inc., Olatec Therapeutics, UCB Biopharma, Vaxxinity, Modag, Peptron, Kissei Pharmaceutical, Cerevel Therapeutics, and others

• Key Parkinson’s Disease Therapies: CREXONT (carbidopa and levodopa) ER capsules, PRODUODOPA (foslevodopa/foscarbidopa), SPN-830 (apomorphine infusion device), Tavapadon, P2B001 (extended-release pramipexole and rasagiline), KM-819, Prasinezumab, P2B001, NPT1220-478, Dapansutrile, UCB7853, UB-312, Emrusolmin, PT320, KDT-3594, Tavapadon, and others

• The Parkinson’s Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Parkinson’s Disease pipeline products will significantly revolutionize the Parkinson’s Disease market dynamics.

 

Parkinson’s Disease Overview

Parkinson’s Disease (PD) is a chronic, progressive neurological disorder that primarily affects movement. It occurs due to the gradual loss of dopamine-producing neurons in the brain, particularly in the substantia nigra region. Common symptoms include tremors, rigidity, slowed movement (bradykinesia), balance difficulties, and postural instability. Non-motor symptoms, such as sleep disturbances, depression, cognitive impairment, and autonomic dysfunction, are also common. While there is no cure, treatments including medications (like levodopa), deep brain stimulation, and lifestyle interventions aim to manage symptoms, improve quality of life, and slow disease progression. Early diagnosis is key for effective management.

 

To Know in detail about the Parkinson’s Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Parkinson’s Disease Market Forecast

 

Parkinson’s Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Parkinson’s Disease Epidemiology Segmentation:

The Parkinson’s Disease market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Total Prevalence of Parkinson’s Disease

• Prevalent Cases of Parkinson’s Disease by severity

• Gender-specific Prevalence of Parkinson’s Disease

• Diagnosed Cases of Episodic and Chronic Parkinson’s Disease

 

Download the report to understand which factors are driving Parkinson’s Disease epidemiology trends @ Parkinson’s Disease Epidemiology Forecast

 

Parkinson’s Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Parkinson’s Disease market or expected to get launched during the study period. The analysis covers Parkinson’s Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Parkinson’s Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Parkinson’s Disease Therapies and Key Companies

• CREXONT (carbidopa and levodopa) ER capsules: Amneal Pharmaceuticals

• PRODUODOPA (foslevodopa/foscarbidopa): AbbVie

• SPN-830 (apomorphine infusion device): Supernus Pharmaceutical/Britannia Pharmaceuticals

• Tavapadon: AbbVie (Cerevel Therapeutics)

• P2B001 (extended-release pramipexole and rasagiline): Pharma Two B

• KM-819: FAScinate Therapeutics

• Prasinezumab: Hoffmann-La Roche

• P2B001: Pharma Two B Ltd.

• NPT1220-478: Neuropore Therapies, Inc.

• Dapansutrile: Olatec Therapeutics

• UCB7853: UCB Biopharma

• UB-312: Vaxxinity

• Emrusolmin: Modag

• PT320: Peptron

• KDT-3594: Kissei Pharmaceutical

• Tavapadon: Cerevel Therapeutics

 

Discover more about therapies set to grab major Parkinson’s Disease market share @ Parkinson’s Disease Treatment Landscape

 

Parkinson’s Disease Market Drivers

• Rising Prevalence: Increasing number of Parkinson’s disease cases globally due to aging populations.

• Growing Awareness: Enhanced awareness among patients and physicians leading to earlier diagnosis and treatment.

• Advancements in Therapies: Introduction of innovative treatments, including dopamine agonists, MAO-B inhibitors, gene therapies, and device-based therapies.

• Expanding Pipeline: Continuous R&D and clinical trials for novel disease-modifying therapies.

• Favorable Reimbursement & Healthcare Access: Improved insurance coverage and government initiatives supporting neurological care.

 

Parkinson’s Disease Market Barriers

• High Treatment Costs: Expensive therapies and device-based interventions limit patient access.

• Side Effects & Safety Concerns: Long-term use of medications may cause complications like dyskinesia and cardiovascular issues.

• Lack of Curative Therapies: Current treatments mainly manage symptoms rather than halt disease progression.

• Complex Diagnosis: Delayed or misdiagnosis due to overlapping symptoms with other neurological disorders.

• Market Fragmentation: Variation in healthcare infrastructure and reimbursement policies across regions.

 

Scope of the Parkinson’s Disease Market Report

• Study Period: 2022–2036

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Parkinson’s Disease Companies: Amneal Pharmaceuticals, AbbVie, Supernus Pharmaceutical/Britannia Pharmaceuticals, AbbVie (Cerevel Therapeutics), Pharma Two B, FAScinate Therapeutics, Hoffmann-La Roche, Neuropore Therapies, Inc., Olatec Therapeutics, UCB Biopharma, Vaxxinity, Modag, Peptron, Kissei Pharmaceutical, Cerevel Therapeutics, and others

• Key Parkinson’s Disease Therapies: CREXONT (carbidopa and levodopa) ER capsules, PRODUODOPA (foslevodopa/foscarbidopa), SPN-830 (apomorphine infusion device), Tavapadon, P2B001 (extended-release pramipexole and rasagiline), KM-819, Prasinezumab, P2B001, NPT1220-478, Dapansutrile, UCB7853, UB-312, Emrusolmin, PT320, KDT-3594, Tavapadon, and others

• Parkinson’s Disease Therapeutic Assessment: Parkinson’s Disease current marketed and Parkinson’s Disease emerging therapies

• Parkinson’s Disease Market Dynamics: Parkinson’s Disease market drivers and Parkinson’s Disease market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Parkinson’s Disease Unmet Needs, KOL’s views, Analyst’s views, Parkinson’s Disease Market Access and Reimbursement

 

To know more about Parkinson’s Disease companies working in the treatment market, visit @ Parkinson’s Disease Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Parkinson’s Disease Market Report Introduction

2. Executive Summary for Parkinson’s Disease

3. SWOT analysis of Parkinson’s Disease

4. Parkinson’s Disease Patient Share (%) Overview at a Glance

5. Parkinson’s Disease Market Overview at a Glance

6. Parkinson’s Disease Disease Background and Overview

7. Parkinson’s Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Parkinson’s Disease

9. Parkinson’s Disease Current Treatment and Medical Practices

10. Parkinson’s Disease Unmet Needs

11. Parkinson’s Disease Emerging Therapies

12. Parkinson’s Disease Market Outlook

13. Country-Wise Parkinson’s Disease Market Analysis (2022–2036)

14. Parkinson’s Disease Market Access and Reimbursement of Therapies

15. Parkinson’s Disease Market Drivers

16. Parkinson’s Disease Market Barriers

17. Parkinson’s Disease Appendix

18. Parkinson’s Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Metro Cellar Door Bilco Pro Shares FHFA Data on a Year of 5.7 Percent Home Value Growth in the New York Area

Following a 5.7 percent annual gain in FHFA's New York-Jersey City-White Plains index, Metro Cellar Door Bilco Pro explains how its installers replace worn sidewalk, Bilco and bulkhead doors.

NEW YORK, NY - November 4, 2026 - Metro Cellar Door Bilco Pro, a cellar door installer that replaces sidewalk cellar doors and Bilco doors on residential and commercial properties in New York City, is sharing Federal Housing Finance Agency (FHFA) house price data for the area, along with guidance for owners with a rusted, loose or leaking cellar door.

The FHFA's all-transactions House Price Index for the New York-Jersey City-White Plains metropolitan division tracks average price changes in repeat sales and refinancings of the same single-family properties.

Area House Prices Through Mid-2026

The FHFA index for the area climbed to 454.16 in the second quarter of 2026, from 429.58 a year earlier, a gain of about 5.7 percent. Readings rose through the year, from 436.06 at the end of 2025 to 441.94 in the first three months of 2026.

The index follows home values over time. It does not measure the condition of any building's entrances or basement doors.

Why Sidewalk Cellar Doors Wear Out

Between foot traffic, water exposure and New York winters, sidewalk doors eventually rust, loosen or become unsafe. When that happens, the company can recommend a replacement door or build a custom cellar door if the opening calls for one, then install a flat cellar door or bulkhead door that sits securely and flush with the sidewalk.

Bulkhead Doors Versus Basement Doors

A bulkhead door usually means an angled exterior door leading to a basement, often mounted over concrete steps or a sloped foundation. These are common on older homes and are sometimes called Bilco doors. A basement door can mean any entry to the basement, including interior doors, exterior doors or egress windows with doors. The company installs both, depending on the layout.

Choosing a Material

For keeping a basement entry dry and secure, the company recommends steel or galvanized steel, which resist rust and last longer in New York City weather than wood, which can warp or rot. Some owners choose powder-coated steel for extra protection. The company also installs moulding, weatherproof seals and custom flashing. The door type, added width, a sloped foundation or uneven concrete, and any foundation or framing repairs can all change the scope of a job.

Metro Cellar Door Bilco Pro's Work in New York City

The replacement process has three steps: the owner schedules an appointment, a team visits to take measurements and discuss options, and once the details are final the door is ordered and an installation date is set. Its installers work on brownstones, rowhouses, townhomes and two-family houses, as well as apartment buildings, storefronts and warehouses, and contractors can work with the company too. Its website says it offers direct-from-manufacturer pricing and lists Queens, Brooklyn, the Bronx and Staten Island among the areas it serves.

About Metro Cellar Door Bilco Pro

Metro Cellar Door Bilco Pro is a cellar door installer in New York City that installs and replaces sidewalk cellar doors, Bilco and bulkhead doors, and fire-rated doors.

Media Contact

Metro Cellar Door Bilco Pro

New York City, NY

(929) 979-7313

https://metrocellardoor.com/

Sources: Federal Housing Finance Agency, House Price Index, all-transactions index by metro area (quarterly): https://www.fhfa.gov/hpi/download/quarterly_datasets/hpi_at_metro.csv ; FHFA HPI datasets page: https://www.fhfa.gov/data/hpi/datasets

Media Contact
Company Name: Metro Cellar Door Bilco Pro
Contact Person: Christopher Long
Email:Send Email
Phone: 929-979-7313
City: New York
State: NY
Country: United States
Website: https://metrocellardoor.com

Clean Slate Hauling And Junk Removal Shares Census Count of 630 New Lacey Housing Units Authorized in 2025

Clean Slate Hauling And Junk Removal has published a guide that pairs U.S. Census Bureau building permit counts for Lacey with how its Lacey crew handles cleanouts, light demolition and construction debris.

LACEY, WA - November 4, 2026 - Clean Slate Hauling And Junk Removal Lacey, a junk removal service for Lacey and the surrounding Thurston County area, is sharing U.S. Census Bureau building permit data for the city, along with guidance for homeowners, landlords and contractors planning a cleanout or remodel.

Every number below is from the Census Bureau's Building Permits Survey, which compiles the new homes and apartments that local permit offices approve each year. This release compares Lacey's 2024 and 2025 annual entries.

New Housing Units Authorized in Lacey

Lacey's permit office approved 630 new housing units in 2025, the survey shows, and most of them were in larger buildings: 602 units in 16 buildings with five or more units, along with 26 single-family homes and 2 units in a duplex.

In 2024, the city authorized 178 new housing units, including 137 units in buildings with five or more units and 37 single-family homes. The 2025 total was more than three times the 2024 figure.

Permit counts measure authorized new construction. They do not count remodels, move-outs or cleanouts in existing homes.

How Estimates and Pricing Work

Clean Slate gives junk removal quotes based on the type and volume of items being removed, and the price is given before any work begins. The company can do a quick on-site review when a job is hard to describe over the phone. For larger jobs, such as a full cleanout of a three-bedroom house, it says pricing depends on volume, access and the kinds of items involved rather than square footage.

Soft Strip, Light Demolition and Debris

People planning a remodel often ask about demolition. Clean Slate explains that a soft strip removes non-structural items such as cabinets, fixtures, flooring and interior materials, while total demolition removes the whole structure. The company's work centers on soft strip and light demolition, such as taking down sheds, decks and small interior structures, followed by hauling. It does not do full building teardowns. Construction debris removal covers wood, drywall, flooring and other materials left after remodeling or repairs.

Clean Slate's Work in Lacey

The company describes its Thurston County work as full-service junk removal. Residential jobs cover old furniture, broken appliances, mattresses and general clutter from houses, apartments and condos. Garage cleanouts cover packed storage, tools, shelving and yard equipment. Property cleanouts help landlords and estate representatives clear rentals, estates and foreclosed homes, and the company offers no-judgment hoarder cleanouts with attention to privacy. On the commercial side, it handles office furniture, storage cleanouts and ongoing pickup for offices, retail spaces and property managers.

Clean Slate sorts loads when it can, separates reusable materials and uses approved facilities for disposal. Its website lists its Lacey service as open 24 hours a day, seven days a week, and it has pages for Lacey, Tumwater, Yelm and North Olympia.

About Clean Slate Hauling And Junk Removal

Clean Slate Hauling And Junk Removal is a junk removal and hauling company in Washington State. From Lacey, its crew covers Tumwater, Yelm and North Olympia with junk removal, cleanouts, light demolition and debris hauling.

Media Contact

Clean Slate Hauling And Junk Removal Lacey

Olympia, WA

(360) 227-8738

https://cleanslatejunk.net/lacey-junk-removal/

Sources: U.S. Census Bureau, Building Permits Survey, annual place data, West Region, 2025: https://www2.census.gov/econ/bps/Place/West%20Region/we2025a.txt ; 2024: https://www2.census.gov/econ/bps/Place/West%20Region/we2024a.txt

Media Contact
Company Name: Clean Slate Hauling And Junk Removal Lacey
Contact Person: Josh Williamson
Email:Send Email
Phone: (360) 227-8738
Address:400 Union Ave SE Suite 209
City: Olympia
State: WA
Country: United States
Website: https://cleanslatejunk.net/lacey/

Charleston Healthspan Shares 2025 Census Bureau Population Estimates for Berkeley County

Charleston Healthspan - Hormones & Peptides has published a guide that pairs the latest U.S. Census Bureau population estimates for Berkeley County with how its Daniel Island practice approaches a first hormone therapy visit.

DANIEL ISLAND, SC - November 4, 2026 - Charleston Healthspan - Hormones & Peptides, a Daniel Island practice that provides hormone therapy for men and women in the Charleston area, is sharing U.S. Census Bureau population estimates for Berkeley County, along with information on how its consultation, services and payment process work.

The guide draws on the Census Bureau's Vintage 2025 population estimates for Berkeley County, which includes Daniel Island.

Berkeley County Population Estimates

Berkeley County's estimated population reached 274,666 on July 1, 2025, a 19.5 percent increase over the April 2020 estimates base of 229,779, the Census Bureau reports. The county had an estimated 110,241 housing units in 2025, and the Census Bureau reports 2,299 building permits for the year.

Residents age 65 and older made up 16.2 percent of the county's population, and those under 18 made up 22.9 percent.

These estimates describe the county's population. They do not say anything about the health needs of any one person.

How a First Visit Works

According to the practice, timing and treatment depend on each patient's symptoms, medical history and lab results. A hormone evaluation comes first, and any plan is built around the individual patient's goals. The website lists symptoms that lead people to ask about therapy, including mood changes, fatigue, low energy and loss of muscle mass. Whether a given treatment is appropriate is a decision made with the provider after an evaluation.

Patients do not have to sign up for a monthly program or annual contract. The practice says it sets each patient's regimen individually.

Payment and Insurance

Charleston Healthspan is an out-of-network provider and does not accept insurance payments for its services. It gives patients a statement listing services with diagnosis, laboratory and procedure codes, which patients can submit to their insurer for possible reimbursement or toward a deductible or flexible spending account. The practice has opted out of Medicare, so patients with Medicare cannot file claims for services there. It does not publish prices and says costs vary by treatment.

Charleston Healthspan's Work in the Charleston Area

The practice's services menu includes bio-identical hormone replacement therapy, including pellet therapy; menopause and andropause care; sexual health care; peptide therapy; GLP-1 therapy and medically supervised weight loss; PRP hair restoration; and postpartum hormone support. The practice states that it uses only bio-identical hormones. Its website names Dr. Susan Kady Wilson as its physician and says she has more than 27 years of experience in hormone replacement therapy.

The main office is at 125 River Landing Dr on Daniel Island, and the website lists additional offices in Summerville and Georgetown.

About Charleston Healthspan - Hormones & Peptides

Charleston Healthspan - Hormones & Peptides is a hormone therapy and wellness practice based on Daniel Island in South Carolina, serving men and women in the Charleston area. The information in this release is general and is not medical advice.

Media Contact

Charleston Healthspan - Hormones & Peptides

125 River Landing Dr, Suite 101, Daniel Island, SC 29492

(843) 375-6588

https://charlestonhealthspan.com/

Sources: U.S. Census Bureau, QuickFacts, Berkeley County, South Carolina (Vintage 2025): https://www.census.gov/quickfacts/berkeleycountysouthcarolina

Media Contact
Company Name: Charleston Healthspan Institute
Contact Person: Dr. Susan K Wilson
Email:Send Email
Phone: 843-375-6588
Address:125 River Landing Dr #101
City: Daniel Island
State: SC 29492
Country: United States
Website: https://charlestonhealthspan.com

AZ Cabinets Shares 2025 Census Population and Housing Data for Phoenix Homeowners Planning Kitchen Cabinets

AZ Cabinets has published a guide that pairs U.S. Census Bureau figures for Phoenix with what its Indian School Road showroom says about choosing, ordering and receiving new cabinets.

PHOENIX, AZ - November 4, 2026 - AZ Cabinets, a cabinet store that sells kitchen and bathroom cabinets to Phoenix homeowners from its showroom at 3301 E Indian School Rd, is sharing U.S. Census Bureau population and housing data for Phoenix alongside guidance on how a cabinet order works, from the first showroom visit to delivery.

The guide draws on the Census Bureau's QuickFacts profile for Phoenix, which combines the Vintage 2025 population estimates with American Community Survey (ACS) 5-year figures for 2020 to 2024.

Phoenix Population and Households

The Census Bureau estimates Phoenix had 1,665,481 residents on July 1, 2025, up 3.6 percent from the April 2020 estimates base of 1,608,349. The ACS counts 610,442 households in the city for 2020 to 2024, with an average of 2.65 people per household.

Phoenix Housing Figures

According to the same profile, 57.3 percent of occupied Phoenix housing units were owner occupied in the 2020 to 2024 period. The median value of an owner-occupied home was $420,700, and median monthly owner costs for homes with a mortgage were $1,847. Median gross rent was $1,582.

Those figures describe the city as a whole. They do not show what any one household spends on a kitchen, and project costs depend on the layout, materials and finishes chosen.

How a Cabinet Order Works

AZ Cabinets describes its process in a few steps. Buying starts in the showroom, where customers look at the selection. They then choose a cabinet style, material and finish, and the AZ Cabinets team takes measurements and prepares a quote. The team can also help plan a layout, whether a homeowner is remodeling an existing kitchen or designing a new one.

The store states that cabinet delivery typically takes two to four weeks after ordering. AZ Cabinets does not install cabinets. It recommends local contractors who do, and handy homeowners can install the cabinets themselves, so the company suggests confirming delivery timing before setting an installation date.

AZ Cabinets' Work in Phoenix

The showroom carries contemporary, traditional, European-style and shaker-style cabinetry. Its semi-custom kitchen cabinets come in materials including plywood, glass, wood, MDF and particle board, and kitchen and bathroom finishes include wood veneers and laminates. Cabinet doors come in solid wood, metal, glass, laminate and plywood, in raised panel, flat panel, shaker and slab styles, and the store stocks hinges, drawer pulls and moldings.

The company also sells wholesale cabinets for homeowners, contractors and designers, and cabinets for offices and entertainment areas. Its website lists Camelback East Village, Central City, Deer Valley, Midtown and Paradise Valley Village among the Phoenix urban villages it serves, and it calls its Indian School Road location its Arcadia showroom. Shipping and delivery are available for all of its products, and warranty coverage varies by product line.

About AZ Cabinets

AZ Cabinets is a cabinet store in Phoenix, Arizona, selling kitchen cabinets, bathroom cabinets, cabinet doors and wholesale cabinets to homeowners, contractors and designers.

Media Contact

AZ Cabinets

3301 E Indian School Rd Ste 103, Phoenix, AZ 85018

(602) 314-6238

https://azcabinetcompany.com/

Sources: U.S. Census Bureau, QuickFacts, Phoenix city, Arizona (Vintage 2025 estimates; ACS 2020-2024): https://www.census.gov/quickfacts/fact/table/phoenixcityarizona/PST045225

Media Contact
Company Name: Cabinets 4 Less – AZ Cabinets
Contact Person: Chris Montoya
Email:Send Email
Phone: (602) 314-6238
Address:3301 E Indian School Rd, Suite 103
City: Phoenix
State: AZ 85018
Country: United States
Website: https://azcabinetcompany.com

Discovery Point Retreat Reports 43% Drop in Client Distress Across Its Full Continuum of Addiction Care

Discovery Point Retreat November 2026 clinical outcomes report

A year of weekly outcomes data from more than 500 adults who moved from residential care into outpatient treatment shows broad gains in depression, anxiety, trauma symptoms and substance use severity.

Dallas, Texas - November 04, 2026 - Discovery Point Retreat (DPR) today released a new year of clinical outcomes data covering October 2025 through October 2026. The data tracks adults in treatment for substance use disorders at DPR's residential facilities in Ennis and Waxahachie and its outpatient center in Dallas. The findings were collected by Discovery Point Retreat, LLC, verified by Discovery MSO, LLC, and prepared for clinical review by Lauren Reisman, LMSW, and Dr. Jerry Vaccaro, M.D.

The headline result comes from 528 adults who received care at both levels: residential treatment at Ennis or Waxahachie, followed by partial hospitalization (PHP) or intensive outpatient (IOP) care in Dallas. From residential admission to outpatient discharge, overall symptom distress fell 43%, and 80.5% of these clients showed improvement.

Every clinical area in the report improved. Across the full continuum, depressive symptoms dropped 49%, anxiety symptoms dropped 38%, and trauma-related distress dropped 40%. Substance use severity, which combines use, cravings and the consequences of use, fell 58%, with 81.6% of clients improving. Relationship functioning improved 30%. Of the clients who arrived with clinically elevated depression, 72.3% scored below the clinical threshold by their last outpatient survey. Clients also rated their care highly, with 95% satisfaction with their treatment experience and their relationship with their care team.

DPR tracks progress with a weekly self-report survey that every program uses. Its questions are aligned with widely used clinical screening tools such as the PHQ-9 for depression and the GAD-7 for anxiety. Because the same survey runs from detox through IOP, the care team can follow each client's progress across levels of care instead of starting over at each step.

Those results compare well against national benchmarks. DPR's survey is modeled on a widely used outcome scale whose developers consider a 10-point drop in symptom distress to be a reliable, meaningful change. Clients who received care across DPR's continuum averaged a 20-point drop. Among those continuum clients who arrived with elevated depression, 67% saw their depression scores fall by half or more, compared with 46% in a national study of 5,554 psychotherapy episodes. DPR is accredited by The Joint Commission, and this year's results draw on 1,886 clients and nearly 10,000 weekly surveys.

Results at each facility also held up on their own. At Ennis, where 740 adults had paired surveys, overall distress fell 35% and 77.7% of clients improved. At Waxahachie, DPR's private-room residential facility, 217 adults saw overall distress fall 31% and substance use severity fall 42%. Both facilities run the same clinical model, with detox followed by residential care that typically lasts four to five weeks.

In Dallas, where clients arrive already stabilized after residential care, the focus shifts to holding those gains while people return to work, family and daily life. Among 739 outpatient clients, substance use severity fell another 26%, and problems at work, school and home tied to use dropped 38%. Peer-group acceptance and participation in a sober lifestyle rose 22%. In the outpatient program, 96% of clients rated their treatment experience and their relationship with their care team highly.

"These numbers come from clients telling us every week how they're doing, so we can see what's working and adjust while someone is still in our care. The biggest takeaway is what happens when people stay connected through the whole continuum. Residential care helps someone stabilize, and outpatient care helps them build on that progress. Our strongest results come from clients who stay with us through both levels of care." — Michael Banis, Chief Growth Officer, Discovery MSO

The outcomes reflect self-reported symptom severity and day-to-day functioning. They are not sobriety or relapse rates.

Adults in Texas looking for detox, residential or outpatient treatment can call Discovery Point Retreat at (855) 635-4776 or contact the admissions team online.

About Discovery Point Retreat

Discovery Point Retreat is a Texas-based addiction treatment provider offering medical detox, residential treatment, partial hospitalization and intensive outpatient care for adults. With residential facilities in Ennis and Waxahachie and an outpatient center in Dallas, DPR provides a full continuum of care for substance use disorders and co-occurring mental health conditions.

Media Contact
Company Name: Discovery Point Retreat
Contact Person: Michael Banis
Email:Send Email
Phone: (855) 635-4776
Address:4306 Capitol Ave
City: Dallas
State: Texas
Country: United States
Website: https://discoverypointretreat.com

Metastatic Melanoma Pipeline Update 2026: Clinical Development Status, Collaborations, and Key Companies to Watch | Evaxion Biotech, InxMed, AiVita Biomedical, Apexigen, Checkmate Pharma, Nektar

(Albany, New York) - November 04, 2026: As per DelveInsight’s assessment, globally, Metastatic Melanoma pipeline constitutes 75+ key companies continuously working towards developing 75+ Metastatic Melanoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

“Metastatic Melanoma Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Metastatic Melanoma Market.

 

The Metastatic Melanoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Metastatic Melanoma Pipeline Report:

• Companies across the globe are diligently working toward developing novel Metastatic Melanoma treatment therapies with a considerable amount of success over the years.

• Metastatic Melanoma companies working in the treatment market are Immatics Biotechnologies, Replimune and Bristol Myers Squibb, Philogen, TILT Biotherapeutics, AiVita Biomedical, Immuneering Corporation, Ultimovacs ASA, MPyxis Oncology, Evaxion Biotech, HUYABIO International, LLC., IO Biotech, Regeneron Pharmaceuticals, IO Biotech, Checkmate Pharmaceuticals, Evaxion Biosciences, Apexigen, Inc., Biocad, Zucero Therapeutics, Karyopharm Therapeutics, Bristol-Myers Squibb, Viralytics, Nykode Therapeutics, and others, are developing therapies for the Metastatic Melanoma treatment

• Emerging Metastatic Melanoma therapies in the different phases of clinical trials are- IMA203, RP1 (vusolimogene oderparepvec) plus nivolumab, Nidlegy, TILT 123, AV-MEL-1, IMM-1-104, UV1, APX005, EVX 01, HBI-8000, IO102-IO103, Fianlimab, IO102-IO103, CMP-001, EVX-01, APX005M, BCD-217, Pixatimod, Selinexor, Relatlimab, V937, VB10.NEO, and others are expected to have a significant impact on the Metastatic Melanoma market in the coming years.

• In October 2026, Faron Pharmaceuticals announced that the final overall survival results from the metastatic melanoma cohort of its Phase I/II MATINS study (NCT03733990) had been accepted for presentation at ESMO 2026. The trial investigated bexmarilimab, an investigational macrophage checkpoint inhibitor, as a monotherapy in 25 patients with metastatic melanoma who had developed resistance to checkpoint inhibitor therapy. The results are expected to provide further clinical support for the ongoing Phase I/II BLAZE trial, which is assessing bexmarilimab in combination with nivolumab in patients with metastatic melanoma and non-small cell lung cancer (NSCLC) who have progressed following anti-PD-1 treatment. The first patient in the BLAZE trial received treatment on October 1, 2026.

• In August 2026, The U.S. FDA granted accelerated approval to Replimune’s Tudriqev (vusolimogene oderparepvec-wtpg), an investigational genetically engineered oncolytic viral therapy, in combination with nivolumab for adults with unresectable advanced cutaneous melanoma whose disease has progressed following treatment with a PD-1-blocking antibody-based regimen. The approval was based on clinical findings showing an objective response rate of 24% among evaluable patients, with a median duration of response of 14.1 months. The therapy is designed to selectively target and destroy cancer cells while activating an antitumor immune response. Continued approval is contingent upon confirmatory clinical evidence from the Phase III IGNYTE-3 trial.

• In July 2026, the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 10–3 in favour of the clinical efficacy evidence supporting RP1 (vusolimogene oderparepvec) in combination with nivolumab for patients with advanced melanoma who experienced disease progression following anti-PD-1 therapy. The committee considered evidence from the IGNYTE clinical trial, including durable responses in heavily pretreated patients. This regulatory milestone preceded the FDA's accelerated approval of the combination in August 2026.

• In July 2026, clinical trial findings reported for advanced melanoma indicated that the combination of tucidinostat, an HDAC inhibitor, and nivolumab, an anti-PD-1 immunotherapy, improved progression-free survival compared with nivolumab alone in previously untreated advanced melanoma patients. The findings highlight the potential of combining epigenetic modulation with immune checkpoint inhibition to enhance antitumor activity. The combination remains investigational and requires further clinical evaluation.

• In June 2026, the US FDA accepted Replimune's Biologics License Application (BLA) resubmission for RP1 (vusolimogene oderparepvec), an investigational oncolytic immunotherapy, in combination with nivolumab for patients with advanced melanoma. The application was classified as a complete Class 1 response, with an FDA action date of August 2, 2026. The therapy is designed to selectively target tumor cells and stimulate antitumor immunity. The regulatory development followed two previous complete response letters and was supported by clinical findings from the IGNYTE study.

• In May 2025, Immatics announced the presentation of updated data from its ongoing Phase Ib trial assessing IMA203 in heavily pretreated metastatic melanoma patients. The company also shared information from a trial-in-progress poster on SUPRAME, the Phase III study evaluating IMA203 in patients with unresectable or metastatic cutaneous melanoma who have previously received checkpoint inhibitor therapy, at ASCO 2025.

 

Metastatic Melanoma Overview

Metastatic Melanoma is an advanced stage of melanoma, a type of skin cancer, where cancer cells spread beyond the original tumor site to distant organs such as the lungs, liver, brain, or bones. It occurs when melanoma cells invade the bloodstream or lymphatic system, leading to secondary tumors. Metastatic melanoma is highly aggressive but can be treated with targeted therapies (BRAF and MEK inhibitors), immunotherapy (checkpoint inhibitors like nivolumab and pembrolizumab), chemotherapy, or radiation therapy. Early detection and advanced treatments have improved survival rates and patient outcomes.

 

Get a Free Sample PDF Report to know more about Metastatic Melanoma Pipeline Therapeutic Assessment:

https://www.delveinsight.com/report-store/metastatic-melanoma-pipeline-insight

 

Emerging Metastatic Melanoma Drugs Under Different Phases of Clinical Development Include:

• IMA203: Immatics Biotechnologies

• RP1 (vusolimogene oderparepvec) plus nivolumab: Replimune and Bristol Myers Squibb

• Nidlegy: Philogen

• TILT 123: TILT Biotherapeutics

• AV-MEL-1: AiVita Biomedical

• IMM-1-104: Immuneering Corporation

• UV1: Ultimovacs ASA

• APX005: MPyxis Oncology

• EVX 01: Evaxion Biotech

• HBI-8000: HUYABIO International, LLC.

• IO102-IO103: IO Biotech

• Fianlimab: Regeneron Pharmaceuticals

 

Metastatic Melanoma Route of Administration

Metastatic Melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Intra-articular

• Intraocular

• Intrathecal

• Intravenous

• Ophthalmic

• Oral

• Parenteral

• Subcutaneous

• Topical

• Transdermal

 

Metastatic Melanoma Molecule Type

Metastatic Melanoma Products have been categorized under various Molecule types, such as

• Oligonucleotide

• Peptide

• Small molecule

 

Metastatic Melanoma Pipeline Therapeutics Assessment

• Metastatic Melanoma Assessment by Product Type

• Metastatic Melanoma By Stage and Product Type

• Metastatic Melanoma Assessment by Route of Administration

• Metastatic Melanoma By Stage and Route of Administration

• Metastatic Melanoma Assessment by Molecule Type

• Metastatic Melanoma by Stage and Molecule Type

 

DelveInsight's Metastatic Melanoma Report covers around 75+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

 

Further Metastatic Melanoma product details are provided in the report. Download the Metastatic Melanoma pipeline report to learn more about the emerging Metastatic Melanoma therapies

 

Some of the key companies in the Metastatic Melanoma Therapeutics Market include:

Key companies developing therapies for Metastatic Melanoma are - Evaxion Biotech, InxMed, AiVita Biomedical, Iovance Biotherapeutics, Viralytics, Merck & Co., Neon Therapeutics, BioNTech, Bristol-Myers Squibb, Ono Pharmaceuticals, Cytovation AS, Biocad, Apexigen, Checkmate Pharmaceutical, Nektar therapeutics, HUYABIO International, LLC., IO Biotech, Bristol Myers Squibb, Karyopharm Therapeutics, Zucero Therapeutics, GlaxoSmithKline, Tesaro, Inc., Ultimovacs ASA, Eucure (Beijing) Biopharma Co., Ltd, Incyte Corporation, Philogen S.p.A., Ascentage Pharma, Exelixis/Ipsen, NovoCure Ltd., Hoffman-La-Roche, Provectus Biopharmaceuticals, BerGenBio ASA, Idera Pharmaceuticals, Celgene Corporation, Novartis, Taizhou Hanzhong biomedical co. LTD, Scancell Ltd, BioMed Valley Discoveries, Inc., Nykode Therapeutics, Sapience Therapeutics, BeiGene, Immunocore, Achilles Therapeutics UK Limited, Vanquish Oncology, Syntrix Biosystems, Inc., TILT Biotherapeutics, PrimeVax Immuno-Oncology Inc., Celldex Therapeutics, Taiga Biotechnologies, Inc., Galectin Therapeutics Inc, Foghorn Therapeutics Inc., TriSalus Life Sciences, Inc., Miltenyi Biomedicine GmbH, CytomX Therapeutics, Inc., Seagen Inc., Immutep, Regeneron pharmaceuticals, Adaptimmune, IDEAYA Biosciences, PokeAcell, Ultimovacs ASA, Verastem, Inc., PACT Pharma, Actuate Therapeutics, Inc., and others.

 

Metastatic Melanoma Pipeline Analysis:

The Metastatic Melanoma pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Melanoma with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Melanoma Treatment.

• Metastatic Melanoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Metastatic Melanoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Melanoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Metastatic Melanoma drugs and therapies

 

Metastatic Melanoma Pipeline Market Drivers

• Improving Healthcare Infrastructure, emergence of effective immune therapies are some of the important factors that are fueling the Metastatic Melanoma Market.

 

Metastatic Melanoma Pipeline Market Barriers

• However, lack Of Cost-Effective Treatment, side effects associated with the treatment and other factors are creating obstacles in the Metastatic Melanoma Market growth.

 

Scope of Metastatic Melanoma Pipeline Drug Insight

• Coverage: Global

• Key Metastatic Melanoma Companies: Immatics Biotechnologies, Replimune and Bristol Myers Squibb, Philogen, TILT Biotherapeutics, AiVita Biomedical, Immuneering Corporation, Ultimovacs ASA, MPyxis Oncology, Evaxion Biotech, HUYABIO International, LLC., IO Biotech, Regeneron Pharmaceuticals, IO Biotech, Checkmate Pharmaceuticals, Evaxion Biosciences, Apexigen, Inc., Biocad, Zucero Therapeutics, Karyopharm Therapeutics, Bristol-Myers Squibb, Viralytics, Nykode Therapeutics, and others

• Key Metastatic Melanoma Therapies: IMA203, RP1 (vusolimogene oderparepvec) plus nivolumab, Nidlegy, TILT 123, AV-MEL-1, IMM-1-104, UV1, APX005, EVX 01, HBI-8000, IO102-IO103, Fianlimab, IO102-IO103, CMP-001, EVX-01, APX005M, BCD-217, Pixatimod, Selinexor, Relatlimab, V937, VB10.NEO, and others

• Metastatic Melanoma Therapeutic Assessment: Metastatic Melanoma current marketed and Metastatic Melanoma emerging therapies

• Metastatic Melanoma Market Dynamics: Metastatic Melanoma market drivers and Metastatic Melanoma market barriers

 

Request for Sample PDF Report for Metastatic Melanoma Pipeline Assessment and clinical trials

 

Table of Contents

1. Metastatic Melanoma Report Introduction

2. Metastatic Melanoma Executive Summary

3. Metastatic Melanoma Overview

4. Metastatic Melanoma- Analytical Perspective In-depth Commercial Assessment

5. Metastatic Melanoma Pipeline Therapeutics

6. Metastatic Melanoma Late Stage Products (Phase II/III)

7. Metastatic Melanoma Mid Stage Products (Phase II)

8. Metastatic Melanoma Early Stage Products (Phase I)

9. Metastatic Melanoma Preclinical Stage Products

10. Metastatic Melanoma Therapeutics Assessment

11. Metastatic Melanoma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Metastatic Melanoma Key Companies

14. Metastatic Melanoma Key Products

15. Metastatic Melanoma Unmet Needs

16 . Metastatic Melanoma Market Drivers and Barriers

17. Metastatic Melanoma Future Perspectives and Conclusion

18. Metastatic Melanoma Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services